

Ester Lozano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5414622/publications.pdf>

Version: 2024-02-01

44
papers

2,656
citations

279798

23
h-index

330143

37
g-index

45
all docs

45
docs citations

45
times ranked

3989
citing authors

#	ARTICLE	IF	CITATIONS
1	Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses. <i>Immunity</i> , 2014, 40, 569-581.	14.3	702
2	The TIGIT/CD226 Axis Regulates Human T Cell Function. <i>Journal of Immunology</i> , 2012, 188, 3869-3875.	0.8	393
3	Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. <i>Arthritis and Rheumatism</i> , 2008, 59, 422-430.	6.7	174
4	TGF- β^2 Induces IL-9 Production from Human Th17 Cells. <i>Journal of Immunology</i> , 2010, 185, 46-54.	0.8	152
5	Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study. <i>Rheumatology</i> , 2011, 50, 2061-2070.	1.9	97
6	Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1481-1487.	0.9	96
7	The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans. <i>Journal of Immunology</i> , 2013, 191, 3673-3680.	0.8	89
8	Blocking interferon β^3 reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1177-1186.	0.9	89
9	Gelatinase expression and proteolytic activity in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1429-1435.	0.9	76
10	Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor β^{\pm} and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Research, 2010, 62, 835-841.	3.4	75
11	Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1581-1588.	0.9	71
12	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 616-623.	0.9	68
13	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1624-1634.	0.9	67
14	Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 434-442.	0.9	59
15	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. <i>Leukemia</i> , 2018, 32, 1427-1434.	7.2	48
16	Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells. <i>FASEB Journal</i> , 2005, 19, 1875-1877.	0.5	46
17	The spectrum of vascular involvement in giant-cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. <i>Apmis</i> , 2009, 117, 10-20.	2.0	44
18	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. <i>Haematologica</i> , 2017, 102, 1776-1784.	3.5	43

#	ARTICLE	IF	CITATIONS
19	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. <i>Cytokine</i> , 2008, 41, 244-253.	3.2	41
20	Influence of Mitochondrial Genetics on the Mitochondrial Toxicity of Linezolid in Blood Cells and Skin Nerve Fibers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	33
21	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 809.	4.8	33
22	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 4688-4698.	7.0	30
23	Five Clinical Conundrums in the Management of Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 819-834.	1.9	26
24	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. <i>Journal of Immunology</i> , 2018, 200, 2581-2591.	0.8	19
25	Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. <i>Haematologica</i> , 2010, 95, 456-463.	3.5	16
26	Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. <i>Frontiers in Genetics</i> , 2020, 11, 497.	2.3	13
27	Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 849-851.	2.5	11
28	Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. , 2019, 7, 259.		10
29	Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma. <i>New England Journal of Medicine</i> , 2006, 355, 1278-1280.	27.0	8
30	Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 238-245.	3.0	5
31	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. <i>PLoS ONE</i> , 2020, 15, e0241778.	2.5	5
32	Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency. <i>Journal of Clinical Medicine</i> , 2021, 10, 3471.	2.4	4
33	Multicentric Standardization of Protocols for the Diagnosis of Human Mitochondrial Respiratory Chain Defects. <i>Antioxidants</i> , 2022, 11, 741.	5.1	4
34	Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1269-1275.	2.0	3
35	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021, 12, 792609.	4.8	3
36	Functionally Relevant Treg Cells Are Present in Giant Cell Arteritis Lesions: Comment on the Article by Samson et al. <i>Arthritis and Rheumatism</i> , 2013, 65, 1133-1134.	6.7	1

#	ARTICLE	IF	CITATIONS
37	BET bromodomain blockade enhances Ikaros inhibition by lenalidomide therapy providing additional activity in in vitro and in vivo models of multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e229-e230.	0.4	1
38	Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity. <i>Blood</i> , 2016, 128, 2115-2115.	1.4	1
39	Interleukin-9 Secretion by Human Th17 Cells is Inducible by TGF- β ² and Proinflammatory Cytokines and is Increased in Autoimmune Diabetes. <i>Clinical Immunology</i> , 2010, 135, S29.	3.2	0
40	Characterization of TCR repertoire of CD4+ and CD8+ T cells from patients with multiple myeloma in sustained complete remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e226-e227.	0.4	0
41	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. <i>Blood</i> , 2015, 126, 4192-4192.	1.4	0
42	BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma. <i>Blood</i> , 2016, 128, 308-308.	1.4	0
43	Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease. <i>Blood</i> , 2018, 132, 3155-3155.	1.4	0
44	Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern. <i>Blood</i> , 2018, 132, 4514-4514.	1.4	0